The next iteration of the Generic Drug User Fee Amendments program should focus on enhancing communications between the US Food and Drug Administration (FDA) and generic drug applicants, industry commenters said. Additionally, some commenters said there should be a dedicated program for complex generic development as part of GDUFA IV....[RAPS]
